DOCS Stock Analysis: Buy, Sell, or Hold?
DOCS - Doximity, Inc.
$23.73
0.04 (0.17%)
▲
5d:
-5.19%
30d:
-3.26%
90d:
-45.69%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When DOCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DOCS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DOCS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$45.53
Based on 4.5% avg growth
INTRINSIC VALUE TODAY
$28.27
16.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DOCS is currently trading at $23.73, which is considered oversold relative to its 30-day fair value range of $24.06 to $25.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.6) compared to its historical average (22.5). Remarkably, the market is currently pricing in an annual earnings decline of 13.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DOCS is in a strong downtrend. The price is currently testing key support at $23.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.55 (+66.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DOCS is in a strong downtrend. The price is currently testing key support at $23.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.55 (+66.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$24.06 -
$25.62
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.6% below Wall St target ($39.55)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$24.06 -
$25.62
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$23.13
Resistance Level
$25.41
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.61
Wall Street Target
$39.55
(+66.6%)
Revenue Growth (YoY)
9.8%
Earnings Growth (YoY)
-16.2%
Profit Margin
37.5%
Valuation Discount vs History
-13.3% cheaper
PE vs Historical
14.6 vs 22.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.3%
(market-implied from PE analysis)
1-Year Target
$21.36
(-10%)
2-Year Target
$19.22
(-19%)
3-Year Target
$17.30
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→23)
$26.63
(+12%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 5.0%)
$42.03
(+77%)
Base:
(SPY PE: 14.6, Growth: 5.0%)
$27.49
(+16%)
Bear:
(PE: 12.4, Growth: 5.0%)
$23.36
(-2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 20.51 | Current EPS (TTM): $1.19
Bull Case
$36.64
(+46%)
Analyst growth 36.4%, PE expands to 22.6
Base Case
$33.31
(+33%)
Market implied 36.4%, PE stable at 20.5
Bear Case
$16.60
(-34%)
Severe decline -20.0%, PE contracts to 17.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.6 to 22.5
Stabilization Target:
$36.53
(+54.0%)
PE Expansion Potential:
+54.0%
Share & Embed Analysis
Last updated: March 31, 2026 12:28 AM ET
Data refreshes hourly during market hours. Next update: 1:28 AM
Data refreshes hourly during market hours. Next update: 1:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DOCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Siddharth Sitaram
SELL
2319 shares
2026-03-10
Kira Scherer Wampler
SELL
2000 shares
2026-03-03
Siddharth Sitaram
SELL
2282 shares
2026-02-10
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$271 | 50 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 54 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 59 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$28 | 58 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$112 | 61 BUY |
